tetano
Editor, Senior Moderator
Signal Transduct Target Ther
. 2020 Sep 22;5(1):212.
doi: 10.1038/s41392-020-00318-0.
Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
Fei Yu[SUP] 1 [/SUP], Rong Xiang[SUP] 1 [/SUP], Xiaoqian Deng[SUP] 1 [/SUP], Lili Wang[SUP] 2 [/SUP], Zhengsen Yu[SUP] 1 [/SUP], Shijun Tian[SUP] 1 [/SUP], Ruiying Liang[SUP] 1 [/SUP], Yanbai Li[SUP] 1 [/SUP], Tianlei Ying[SUP] 3 [/SUP], Shibo Jiang[SUP] 4 [/SUP]
Affiliations
Abstract
The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.
. 2020 Sep 22;5(1):212.
doi: 10.1038/s41392-020-00318-0.
Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
Fei Yu[SUP] 1 [/SUP], Rong Xiang[SUP] 1 [/SUP], Xiaoqian Deng[SUP] 1 [/SUP], Lili Wang[SUP] 2 [/SUP], Zhengsen Yu[SUP] 1 [/SUP], Shijun Tian[SUP] 1 [/SUP], Ruiying Liang[SUP] 1 [/SUP], Yanbai Li[SUP] 1 [/SUP], Tianlei Ying[SUP] 3 [/SUP], Shibo Jiang[SUP] 4 [/SUP]
Affiliations
- PMID: 32963228
- DOI: 10.1038/s41392-020-00318-0
Abstract
The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.